Consistent with its mission and guiding principles, CAMP maintains a high level of commitment to working closely with regulatory agencies such as the U.S. Food and Drug Administration. CAMP acknowledges that there are regulatory aspects to many of the cutting-edge technologies being identified, researched, and developed and considers the FDA as both a customer and a partner.
Highlights
- Moheb Nasr (FDA CDER) and Ajaz Hussain (Deputy Division Director, FDA Division of Pharmaceutical Sciences) join CAMP Meeting, February 2005.
- Janet Woodcock (Head, FDA CDER), Ajaz Hussain (Deputy Division Director, FDA Division of Pharmaceutical Sciences), and David Horowitz join CAMP Meeting, March 2003.
- Ray Scherzer, Vice-President, GlaxoSmithKline (CAMP Member Company) speaks at FDA Science Board Meeting, April 2002.
- Janet Woodcock (Head, FDA CDER) joins CAMP Annual Meeting, March 2002 to discuss Process Analytical Technology.
- Ajaz Hussain (Deputy Division Director, FDA Division of Pharmaceutical Sciences) joins CAMP Annual Meeting, March 2002 to discuss Process Analytical Technology.
- G. K. Raju, Executive Director, MIT Pharmaceutical Manufacturing Initiative (PHARMI), speaks at FDA Science Board Meeting, November 2001.
FDA GMP Subcommittee
In addition, several CAMP associates are active members of the FDA Good Manufacturing Practice (GMP) Subcommittee:
- Garnet Peck, Ph.D. (Purdue)
- G. K. Raju, Ph.D. (CAMP, Light Pharma, MIT, Purdue)